Stratec Se

Stratec Se Rule of 40

The Rule of 40 of Stratec Se (SBS.DE) as of Oct 28, 2026 is 0.80 %. In the previous year, Rule of 40 was 6.21 % — a change of -87.09% (lower).

Rule of 40

0.80 %

YoY

-87.09%

Last updated:

Rule of 40 of Stratec Se is 2025 0.80 % . Rule of 40 of Stratec Se was 2024 6.21 % . It decreases by -87.09% lower compared to the previous year.

The Stratec Se Rule of 40 history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Rule of 40
Date
Rule of 40
Jan 1, 2018
-2.27 EUR
Jan 1, 2019
26.22 EUR
Jan 1, 2020
26.24 EUR
Jan 1, 2021
32.16 EUR
Jan 1, 2022
10.87 EUR
Jan 1, 2023
8.87 EUR
Jan 1, 2024
6.21 EUR
Jan 1, 2025
0.80 EUR
The Stratec Se Rule of 40 history
YEARRule of 40YoY
0.80 %-87.09%
6.21 %-29.97%
8.87 %-18.42%
10.87 %-66.20%
32.16 %+22.57%
26.24 %+0.07%
26.22 %-1,254.43%
-2.27 %-108.12%
27.99 %-28.20%
38.98 %+97.90%
19.70 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Stratec Se Stock analysis

What does Stratec Se do? The company Stratec SE is a German company operating in the medical technology industry. It was founded in 1984 and has since become a leading provider of automation solutions and diagnostic instruments. Stratec's business model is based on the development and production of devices and systems used in medical diagnostics. The company focuses in particular on the areas of immunology, clinical chemistry, and hematology. Stratec also offers innovative solutions in microscopy and cell analysis. In the "automation solutions" division, Stratec develops systems for the automation of laboratory processes. These are mainly used in clinical diagnostics to accelerate and simplify workflow. Examples include sample identification systems, pipetting robots, and analysis devices. In the "in vitro diagnostics" division, Stratec offers products for determining blood values. This includes devices for determining glucose, cholesterol, and hemoglobin levels, as well as devices for infection diagnostics and tumor and allergy diagnostics. Another division of Stratec is "microscopy." The company manufactures automated microscope systems, primarily used in biomedical research to analyze cells and tissues. In the "cell analysis" division, Stratec offers innovative methods for analyzing cells, such as cell growth and vitality determination. Stratec always focuses on tailoring the design of its products to the needs of its customers. High flexibility in device development and manufacturing is therefore an important factor in the company's success. In addition to device development and production, Stratec also provides services related to its products. These include installation, maintenance, and on-site repair of devices for customers. Stratec SE operates internationally and has branches in Europe, Asia, and America. The company employs over 1,000 people worldwide. Overall, Stratec SE is a successful and renowned provider of medical devices and systems for automating laboratory processes. With its diverse product portfolio and high flexibility in customer support, Stratec has earned a leading position in the industry. Stratec Se is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Stratec Se stock

Rule of 40 of Stratec Se is 0.80 % in 2025.

On Eulerpool you can find the complete historical development of Rule of 40 Stratec Se since 2006 – with annual values, charts, and detailed analysis.

The Rule of 40 states that a company's revenue growth rate plus profit margin should exceed 40%. It is widely used to evaluate SaaS and high-growth companies.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Quality — Stratec Se

All Key Metrics — Stratec Se